Resource Consumption and Health Care Costs of Herpes Zoster and Postherpetic Neuralgia in Germany

被引:3
|
作者
Schiffner-Rohe, J. [1 ]
Koster, I. [2 ]
Beillat, M. [3 ]
Lilie, H. M. [4 ]
Schubert, I. [5 ]
机构
[1] Sanofi Pasteur MSD GmbH, Leimen, Germany
[2] Univ Cologne, PMV Forschungsgruppe Klin, Cologne, Germany
[3] Univ Cologne, Poliklin Psychiatrie & Psychotherapie Kindes & Ju, Cologne, Germany
[4] Sanofi Pasteur MSD SNC, Lyon, France
[5] Niedergelassene Facharztin Dermatol & Venerol, Hamburg, Germany
来源
关键词
Herpes zoster; postherpetic neuralgia; resource consumption; health care costs;
D O I
10.1055/s-0029-1245896
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Aim: Herpes zoster (HZ, shingles) often occurs after the 50th year of age, and characteristic skin lesions, pain and dysesthesias are the predominant symptoms. While the associated acute and chronic pain does not only have a considerable impact on the health related quality of life of the persons, the primary therapy of HZ as well as the analgesic therapy also cause costs for the health care system and the society. The aim of the present analysis was to assess the consumption of resources and the costs of HZ and its complication postherpetic neuralgia (PHN) on the basis of routine health care data of a German statutory health insurance. Method: Immune-competent patients above the age of 50 years with a first diagnosis of HZ or PHN in 2004 were identified by the ICD-10 encoded diagnosis from the data of the Statutory Health Insurance (SHI) sample AOK Hesse/KV Hesse. After the identification of cost-relevant categories like physician contacts, diagnostic investigations, prescribed medications, hospital care, benefits in kind and sick leave, the patient-related costswere specified from SHI perspective (direct costs) and societal perspective (direct and indirect costs). Costs due to hospital care and sick leave could be directly attributed to the diagnosis, costs due to physician contacts, diagnostic tests and benefits in kind were estimated as excess costs per patient in the year after the HZ diagnosis compared to the year before HZ diagnosis. Results: The average excess costs per HZ-case in 2004 were 593.15 (sic), per PHN-case 1762.51 (sic). Thus, PHN led to significantly higher costs. The direct costs of HZ and PHN increased with age. Indirect costs due to sick leave were highest in the group of 50 - 59 year old patients and account for the highest proportion of total costs in this age group. Conclusion: Due to demographic ageing, i.e. the proportion of older people within the German population, a rise in costs as a result of HZ and PHN for the health care system and the society is expected. In addition, indirect costs due to sick leave caused by HZ/PHN will presumably increase rather than decrease.
引用
收藏
页码:216 / 223
页数:8
相关论文
共 50 条
  • [1] Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany
    Ultsch, Bernhard
    Koester, Ingrid
    Reinhold, Thomas
    Siedler, Anette
    Krause, Gerard
    Icks, Andrea
    Schubert, Ingrid
    Wichmann, Ole
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2013, 14 (06): : 1015 - 1026
  • [2] Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany
    Bernhard Ultsch
    Ingrid Köster
    Thomas Reinhold
    Anette Siedler
    Gérard Krause
    Andrea Icks
    Ingrid Schubert
    Ole Wichmann
    The European Journal of Health Economics, 2013, 14 : 1015 - 1026
  • [3] HEALTH ECONOMIC EVALUATION OF THE VACCINATION AGAINST HERPES ZOSTER AND POSTHERPETIC NEURALGIA IN GERMANY
    Ultsch, B.
    Reinhold, T.
    Siedler, A.
    Krause, G.
    Wichmann, O.
    VALUE IN HEALTH, 2012, 15 (07) : A394 - A394
  • [4] Herpes zoster and postherpetic Neuralgia
    Wollina, U.
    Machetanz, J.
    HAUTARZT, 2016, 67 (08): : 653 - 663
  • [5] The spectrum of health care costs associated with herpes zoster: Acute pain vs. postherpetic neuralgia
    Hawkins, K.
    White, R.
    Dworkin, R.
    O'connor, A.
    Baser, O.
    VALUE IN HEALTH, 2007, 10 (03) : A173 - A173
  • [6] Herpes zoster and postherpetic neuralgia
    Watson, C. Peter N.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2010, 182 (16) : 1713 - 1714
  • [7] Herpes zoster and postherpetic neuralgia
    Johnson, Robert W.
    EXPERT REVIEW OF VACCINES, 2010, 9 (03) : 21 - 26
  • [8] Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany
    Ultsch, Bernhard
    Weidemann, Felix
    Reinhold, Thomas
    Siedler, Anette
    Krause, Gerard
    Wichmann, Ole
    BMC HEALTH SERVICES RESEARCH, 2013, 13
  • [9] Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany
    Bernhard Ultsch
    Felix Weidemann
    Thomas Reinhold
    Anette Siedler
    Gérard Krause
    Ole Wichmann
    BMC Health Services Research, 13
  • [10] Reduction of postherpetic neuralgia in herpes zoster
    Vander Straten, M
    Carrasco, D
    Lee, P
    Tyring, SK
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2001, 5 (05) : 409 - 416